EPHA3 and kidney cancer: A groundbreaking assertion is made that elevated EphA3 expression independently heightens the risk of poor prognosis in KIRP patients, while concurrently functioning as a regulator of the immune microenvironment as well as a viable biomarker for prognostic evaluation and the assessment of immunotherapy response in patients with kidney cancer.